SARDs are a heterogeneous group of disorders characterized by dysregulation of the immune system, that starts to turn against the body’s own tissues. Major SARDs include systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis and Sjögren’s syndrome. These diseases can affect multiple organs and share common symptoms such as fatigue, fever, joint pain and skin rash. Diagnosis relies on a combination of clinical assessment and specific autoantibody tests. Early diagnosis is crucial to initiate appropriate therapy and slow down disease progression.
Anti-cN1A autoantibodies are directed against cytoplasmic 5′-nucleotidase 1A (cN1A), a protein involved in the hydrolysis of adenosine monophosphate and that has a role in the physiological regulation of energy balance, metabolic control, and cell replication. Anti-cN1A autoantibodies are found in 33–34% of patients with inclusion body myositis (IBM). Although they may also be found in other autoimmune diseases, the rarity of anti-cN1A in patients affected by PM and DM makes them a key marker to differentiate between myositis subtypes. As a result, their serological detection is highly relevant for identifying distinct clinical phenotypes, stratifying prognosis and guiding therapeutic management.
Serum, EDTA plasma, heparin plasma, citrate plasma
Immunoblot
Fasting for at least 8-12 hours before sampling
Refer to the Health Service Charter to check storage conditions
+2/+8°C
This test provides the quantitative determination of total tau protein to support the diagnosis of Alzheimer’s disease.
This test provides the quantitative determination of tau protein phosphorylated at threonine 181 (pTau181), to support the diagnosis of Alzheimer’s disease.
Test for the determination of human autoantibodies against NMDAR to support the diagnosis of paraneoplastic neurological syndromes with an intermediate-risk phenotype.
Subscribe to our newsletter to be always updated.